United Therapeutics Corporation (UTHR)

Over the past six months, United Therapeutics' stock price has been impacted by several events. In September 2025, the stock surged by 33% following positive late-stage clinical trial results for Tyvaso in idiopathic pulmonary fibrosis (IPF). In June 2025, United Therapeutics and Intermountain Health announced the first patient treated in a clinical study using a bioengineered external liver assist product. In October 2025, United Therapeutics reported record third-quarter 2025 financial results. In November 2025, the company announced the first transplant in the EXPAND clinical trial of UKidney in patients with end-stage renal disease. Throughout the period, the company participated in several investor conferences. Between January 6, 2025, and January 2, 2026, UTHR's share price increased by 39.77%.

Specific detailed information regarding the demand seasonality for United Therapeutics' products and services is not explicitly provided in the available search results. While some financial platforms indicate that seasonality data exists for UTHR to identify patterns in monthly returns, access to this detailed information typically requires a registered account. Therefore, specific seasonal demand patterns for United Therapeutics' products are not publicly detailed in the provided information.

United Therapeutics Corporation is an American biotechnology company focused on developing treatments for chronic and life-threatening diseases, operating in the Pharmaceuticals and Healthcare sector, specifically in the Biotechnology industry. Its core business areas include pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), neuroblastoma, and end-stage lung disease, with a focus on organ transplantation and manufacturing. Major products include Tyvaso (treprostinil), Remodulin (treprostinil), Orenitram (treprostinil), Adcirca (tadalafil), and Unituxin. The company also engages in innovative research and development, including xenotransplantation and the development of bioengineered organs.

United Therapeutics has a global presence with facilities in the United States, Canada, and the United Kingdom. In the U.S., the company's co-headquarters are located in Silver Spring, Maryland, and Research Triangle Park, North Carolina. Additional U.S. facilities are in Melbourne and Jacksonville, Florida; Manchester, New Hampshire; Blacksburg, Virginia; and Washington, D.C. Canadian operations include facilities in Magog and Bromont, Quebec.

United Therapeutics has maintained a positive brand reputation over the past year. In December 2023, Newsweek named United Therapeutics one of "America's Most Responsible Companies 2024". In April 2025, Great Place to Work® and Fortune magazine recognized United Therapeutics as one of the "Fortune 100 Best Companies to Work For® in 2025", ranking it 73rd nationally. No significant negative events impacting United Therapeutics' reputation in the past year were found in the provided information.

United Therapeutics Corporation has significant institutional ownership, with approximately 77.65% to 94.94% of the company's stock held by institutional shareholders, including BlackRock, Inc., Vanguard Group Inc, Renaissance Technologies Llc, Avoro Capital Advisors LLC, State Street Corp, Wellington Management Group Llp, and Geode Capital Management, Llc. Individual and insider ownership accounts for a smaller percentage, with Eli Lilly Co and Martine A. Rothblatt identified as notable individual/insider shareholders.